1. Purpose of the PSP and background. 2. Aims and objectives of the Psoriasis PSP
|
|
- Margery Lawson
- 5 years ago
- Views:
Transcription
1 Psoriasis Priority Setting Partnership PROTOCOL [14/07/] 1. Purpose of the PSP and background This protocol sets out the aims, objectives and commitments of the Psoriasis Priority Setting Partnership (PSP) and the basic roles and responsibilities of the partners therein. It is agreed that the Protocol is reviewed by the Steering Group and updated on a regular basis. The James Lind Alliance (JLA) is a non-profit making initiative, established in It brings patients, carers and clinicians together in Priority Setting Partnerships (PSPs). These partnerships identify and prioritise uncertainties, or unanswered questions, about the effects of treatments that they agree are the most important. The aim of this is to help ensure that those who fund health research are aware of what really matters to both patients and clinicians. The National Institute for Health Research (NIHR funds the infrastructure of the JLA to oversee the processes for priority setting partnerships, based at the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC), University of Southampton. The Psoriasis PSP was made possible following investment and funding of the partnership by the Psoriasis Association and will be led by Dr Helen Young (Clinical Senior Lecturer in Dermatology and Consultant Dermatologist) who is based at The Centre for Dermatology Research at The University of Manchester. 2. Aims and objectives of the Psoriasis PSP The aim of the Psoriasis PSP is to identify the unanswered questions about psoriasis treatment from patient and clinical perspectives and then prioritise those that patients and clinicians agree are the most important. The objectives of the Psoriasis PSP are to: work with patients and clinicians to identify uncertainties about psoriasis including childhood and adult psoriasis; all severities of psoriasis; all areas of the body (scalp/nails/flexures); psoriatic arthritis; comorbidities; pathways / access to care; treatments; lifelong management strategies. Excluded from the scope of the psoriasis PSP palmoplantar pustular psoriasis to agree by consensus a prioritised list of those uncertainties, for research to publicise the results of the PSP and process to take the results to research commissioning bodies to be considered for funding. 1
2 3. The Steering Group The Partnership and the priority setting process will be supported and guided by The James Lind Alliance (JLA). The Steering Group includes representation of patient/carer groups and clinicians. The Steering Group will agree at the initial steering group meeting, the resources, including time and expertise that they will contribute to each stage of the process. The Psoriasis PSP Steering Group will be led and managed as follows: Chair Maryrose Tarpey - JLA Advisor Funding body Helen McAteer - Psoriasis Association Carla Renton - Psoriasis Association Patient representatives Paul Fitzpatrick Carolyn Hughes Vanessa Lawrence-French Alison Austin - patient and parent representative Damini Mistry Brian Rochford Clinician representatives Helen Young Psoriasis PSP Lead, Consultant Dermatologist (The University of Manchester) Christopher Griffiths - Consultant Dermatologist (The University of Manchester) Joyce Leman - Consultant Dermatologist (Scotland) Christine Bundy Psychologist (Cardiff) Julie Van Onselen Dermatology Nursing (Oxfordshire) Lucy Moorhead - Advanced Nurse Practitioner in Dermatology (St John s, London) Emma Le Roux - Primary Care (Bristol) PSP Rabiya Majeed-Ariss Psoriasis PSP Investigator, The University of Manchester Naomi Wells Psoriasis PSP co-ordinator, The University of Manchester Maggie McPhee - UK DCTN (University of Nottingham) 2
3 Douglas Grindlay UK DCTN (University of Nottingham) The Psoriasis PSP will involve close collaboration with colleagues from the UKDCTN based at the University of Nottingham s Centre for Evidence Based Dermatology. This group have significant experience in conducting other dermatology focused PSPs including those on hidradenitis suppurativa and eczema. The UKDCTN team will support the psoriasis PSP through sharing of their previous experience, Identification and invitation of potential PSP partners and Steering Group members, supporting the dissemination of the initial survey and providing access to expertise for the assembly and categorisation of collated indicative questions, uncertainty checking and priority setting stages of the process. A schedule of the SG meetings is included in Appendix A. 4. The wider Partners Organisations and individuals will be invited to be involved with the PSP as partners. Partners are groups or individuals who will commit to supporting the PSP by disseminating the PSP survey and helping the PSP to gather questions and uncertainties of practical clinical importance relating to the treatment and management of Psoriasis. Partners will represent the following groups: people who have had Psoriasis carers of people who have had Psoriasis medical doctors, nurses and professionals allied to medicine with clinical experience of Psoriasis It is important that all organisations which can reach and advocate for these groups should be invited to become involved in the PSP. The JLA Adviser will take responsibility for ensuring the various stakeholder groups are able to contribute equally to the process. Exclusion criteria Some organisations may be judged by the JLA or the Steering Group to have conflicts of interest. These may be perceived to adversely affect those organisations views, causing unacceptable bias. As this is likely to affect the ultimate findings of the PSP, those organisations will not be invited to participate. It is possible, however, that interested parties may participate in a purely observational capacity when the Steering Group considers it may be helpful. The following groups have already committed to partnership with the Psoriasis PSP: The British Association of Dermatologists The British Dermatological Nursing Group The Primary Care Dermatology Society The International Psoriasis Council 5. The methods the PSP will use This section describes a schedule of proposed stages through which the PSP aims to fulfil its objectives. The process is iterative and dependent on the active participation and contribution of different groups. The methods 3
4 adopted in any stage will be agreed through consultation between the Steering Group members, guided by the PSP s aims and objectives. More details can be found in the Guidebook section of the JLA website at where examples of the work of other JLA PSPs can also be seen. Step 1: Identification and invitation of potential partners Potential partner organisations will be identified through a process of peer knowledge and consultation, through the Steering Group members networks. Potential partners will be contacted and informed of the establishment and aims of the Psoriasis PSP and may be invited to participate. Step 2: Initial stakeholder meeting The initial stakeholder meeting will have several key objectives: to welcome and introduce potential members of the Psoriasis PSP to present the proposed plan for the PSP to initiate discussion, answer questions and address concerns to identify those potential partner organisations which will commit to the PSP and identify individuals who will be those organisations representatives and the PSP s principal contacts to establish principles upon which an open, inclusive and transparent mechanism can be based for contributing to, reporting and recording the work and progress of the PSP. Step 3: Identifying treatment uncertainties The PSP will identify questions and uncertainties of practical clinical importance relating to the treatment and management of Psoriasis. A period of up to 4 months will be given to complete this exercise. Decisions on closing the survey ahead of this time point will be taken by the SG. A postal and web-based survey will be used. Existing sources of information about treatment uncertainties for patients and clinicians will be searched in this initial survey. These can include question-answering services for patients and carers and for clinicians; research recommendations in systematic reviews and clinical guidelines; protocols for systematic reviews being prepared and registers of ongoing research. The starting point for identifying sources of uncertainties and research recommendations is NHS Evidence: Step 4: Refining questions and uncertainties The consultation process through the initial survey will produce raw unanswered questions about diagnosis and the effects of treatments. These raw questions will be assembled and categorised and refined by Rabiya Majeed-Ariss (Psoriasis PSP Investigator, The University of Manchester) into collated indicative questions which are clear, addressable by research and understandable to all. Similar or duplicate questions will be combined where appropriate. Systematic reviews and guidelines will be identified and checked by Rabiya Majeed-Ariss and the steering group to see to what extent these refined questions have, or have not, been answered by previous research. The recency of existing evidence will be an important consideration. Evidence published in the last 5 years will be considered sufficiently recent. Sometimes, uncertainties are expressed that can in fact be resolved with reference to existing research evidence i.e. they are "unrecognised knowns" and not uncertainties. If a question about treatment effects can be answered with existing information but this is not known, it suggests 4
5 that information is not being communicated effectively to those who need it. Accordingly, the JLA recommends strongly that PSPs keep a record of these 'answerable questions' and deal with them separately from the 'true uncertainties' considered during the research priority setting process. Uncertainties which are not adequately addressed by previous research will be collated and recorded on a template (supplied by the JLA) by Rabiya Majeed-Ariss. This will demonstrate the checking undertaken to make sure that the uncertainties have not already been answered. Further uncertainties identified when checking existing systematic review evidence will be added to this list. The data will be submitted to the JLA for publication on its website on completion of the priority setting exercise, taking into account any changes made at the final workshop, in order to ensure that PSP results are publicly available. Step 5: Prioritisation interim and final stages The aim of the final stage of the priority setting process is to prioritise through consensus the identified uncertainties relating to the treatment or management of Psoriasis. This will be carried out by members of the Steering Group and the wider partnership that represents patients and clinicians. The interim stage, to proceed from a long list of uncertainties (e.g. up to 80 questions) to a shorter list (e.g. up to 20 questions) to be discussed at the final priority setting workshop, will be carried out in a second survey by post or online, whereby organisations consult their membership and choose and rank their top 10 most important uncertainties. There are examples of how other PSPs have achieved this at Individuals who have completed the initial survey and agreed to be re-contacted will be informed of the second survey and invited to participate. The final stage, to reach, for example, 10 prioritised uncertainties, will be conducted in a face-to-face meeting, using group discussions and plenary sessions. The methods used for this prioritisation process will be determined by consultation with the partner organisations and with the advice of the JLA Adviser. The JLA will facilitate this process and ensure transparency, accountability and fairness. Participants will be expected to declare their interests in advance of this meeting. A timeline is included as Appendix B. 6. Dissemination of findings and research Findings and research It is anticipated that the findings of the Psoriasis PSP will be reported to funding and research agenda setting organisations such as the NIHR and the major research funding charities. Steering Group members and partners are expected to develop the prioritised uncertainties into research questions, and to work to establish the research needs of those unanswered questions to use when approaching potential funders, or when allocating funding for research themselves, if applicable. 1 Publicity As well as alerting funders, partners and Steering Group members are encouraged to publish the findings of the Psoriasis PSP using both internal and external communication mechanisms. The Steering Group may capture and publicise the results through descriptive reports of the process itself in Plain English. This exercise will be distinct from the production of an academic paper, which the partners are also encouraged to do. However, production of an academic paper should not take precedence over publicising of the final results. 1 Add further detail here about how and where the priorities will be developed and researched. 5
6 7. Agreement of the Steering Group Signed by the Steering Group The undersigned agree to follow the [health problem] Priority Setting Protocol. [Insert name and organisation] Date:.. [Insert name and organisation] Date:.. [Insert name], The James Lind Alliance Date:.. 6
7 Appendix A: Schedule of Steering Group Meetings Face to face meeting Teleconference meeting * Monday, 19 th June 20 * Friday, 14 th July 20 * Friday, 25 th August 20 * Tuesday, 12 th September 20 * Tuesday, 7 th November 20 * Tuesday, 12 th December 20 * Tuesday, 23 rd January 20 * Tuesday, 6 th March 20 * Tuesday, th April 20 * Tuesday, 5 th June 20 ok * Tuesday, 3 rd July 20 * Tuesday, 4 th September 20 * Tuesday, 23 rd October 20 7
8 Appendix B: Timeline TASK Apr May START Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Invite people to SG Invite partners Draft survey Draft protocol Draft SG Terms of Ref. Face to face/teleconf SG Meetings*** Finalise protocol and survey, SG sign off Prepare PSP website, promotion and publicity strategy Pilot Survey 1 to collect uncertainties* Agree Survey 1 Activate publicity mechanisms Survey 1 open nationally Analyse Survey 1: Refine uncertainties and generate long list. SG sign off Interim priority setting exercise: Open Survey2 Analyse Survey 2: SG agree and sign off short list of q s for w/shop Priority setting workshop Publication and results dissemination Conference P.A. Gene presentation 1/52 to Cl** *To coincide with 4-6 July Liverpool Annual Meeting of the British Assn of Dermatologists (Psoriasis Association will house PSP survey at their conference stand. **For Psoriasis from Gene to Clinic Meeting 30 Nov-2 Dec 20 ***Schedule for Steering Group meetings in Appendix A Aug Sep Oct FINISH BSID BAD P.A. wk. 8
MS Priority Setting Partnership. PROTOCOL August 2012
MS Priority Setting Partnership PROTOCOL August 2012 Purpose The purpose of this protocol is to set out the aims, objectives and commitments of the MS Priority Setting Partnership (PSP) and the basic roles
More informationDementia Priority Setting Partnership. PROTOCOL March 2012
Dementia Priority Setting Partnership PROTOCOL March 2012 Purpose The purpose of this protocol is to set out the aims, objectives and commitments of the Dementia Priority Setting Partnership (PSP) and
More informationKidney Transplantation
James Lind Alliance Priority Setting Partnership in Kidney Transplantation PROTOCOL Version 1.4 12 th June 2014 Purpose The purpose of this protocol is to set out the aims, objectives and commitments of
More informationProstate Cancer Priority Setting Partnership. PROTOCOL June 2009
Prostate Cancer Priority Setting Partnership PROTOCOL June 2009 Purpose The purpose of this protocol is to set out the aims, objectives and commitments of the Prostate Cancer Priority Setting Partnership
More informationEmergency Medicine Priority Setting Partnership. PROTOCOL (Version 1: )
Emergency Medicine Priority Setting Partnership PROTOCOL (Version 1: 22.10.2015) Purpose The purpose of this protocol is to set out the aims, objectives and commitments of the Emergency Medicine Priority
More information1. Purpose of the Pessary PSP and background
Pessary Priority Setting Partnership PROTOCOL May 2016 1. Purpose of the Pessary PSP and background The purpose of this protocol is to set out the aims, objectives and commitments of the Pessary Priority
More informationStudy protocol. Version 1 (06 April 2011) Ethics ref: R&D ref: UK CRC portfolio ID:
Identifying and prioritising important research questions for the treatment of eczema a collaborative partnership between patients, carers, clinicians and researchers Study protocol Version 1 (06 April
More information1. Purpose of the PSP and background
Advanced Heart Failure Priority Setting Partnership PROTOCOL V1.5 13.03.18 1. Purpose of the PSP and background The purpose of this protocol is to set out the aims, objectives and commitments of the Advanced
More information1. Purpose of the PSP and background
Lichen Sclerosus Priority Setting Partnership PROTOCOL November 2017 1. Purpose of the PSP and background The purpose of this protocol is to set out the aims, objectives and commitments of the Lichen Sclerosus
More informationHair Loss Priority Setting Partnership
Hair Loss Priority Setting Partnership Establishing and Prioritising Research Questions for the Treatment of Hair Loss (Alopecia) PROTOCOL Version 1.7 (5 June 2014) Abby Macbeth Specialist Registrar in
More informationJames Lind Alliance Oral and Dental Health Priority Setting Partnership Protocol
James Lind Alliance Oral and Dental Health Priority Setting Partnership Protocol Purpose The purpose of this protocol is to set out the aims, objectives and commitments of the Oral and Dental Health Priority
More informationThe James Lind Alliance (JLA) Tackling treatment uncertainties together
The James Lind Alliance (JLA) Tackling treatment uncertainties together The JLA infrastructure is funded by the NIHR The James Lind Alliance The James Lind Alliance (JLA) is a non-profitmaking initiative,
More informationWhat are some of the future priorities for dementia research?
What are some of the future priorities for dementia research? Overview of the process How did the project start? What did we do - methods Prioritisation Next steps History of initiative Public health representation
More informationEstablishing and Prioritising Research Questions for the Treatment of Alopecia Areata: The Alopecia Areata Priority Setting Partnership
Establishing and Prioritising Research Questions for the Treatment of Alopecia Areata: The Alopecia Areata Priority Setting Partnership Summary Background Alopecia areata is a common hair loss disorder
More informationMeasuring the impact of patient and public involvement in the JLA Kidney Transplant PSP
Measuring the impact of patient and public involvement in the JLA Kidney Transplant PSP Contents Measuring the impact of patient and public involvement in the JLA Kidney Transplant PSP... 1 Overview and
More informationBeccy Maeso, The James Lind Alliance The James Lind Alliance Perspective
Beccy Maeso, The James Lind Alliance The James Lind Alliance Perspective The James Lind Alliance Tackling treatment uncertainties together Beccy Maeso James Lind Alliance JLA Priority Setting Partnerships
More informationPalliative and end of life care Priority Setting Partnership
Palliative and end of life care Priority Setting Partnership Putting patients, carers and clinicians at the heart of research Katherine Cowan, James Lind Alliance Dr Bill Noble, Marie Curie Palliative
More informationSETTING PRIORITIES FOR TYPE 1 DIABETES RESEARCH WORKSHOP
SETTING PRIORITIES FOR TYPE 1 DIABETES RESEARCH WORKSHOP Report of a workshop held on the 24 th May 2011 at Friends House, London Prepared by Sally Crowe James Lind Alliance (JLA) June 2011 1. The Type
More informationInvolving patients in research experiences from the eczema priority setting partnership
Involving patients in research experiences from the eczema priority setting partnership Professor Kim Thomas, Deputy Director Centre of Evidence Based Dermatology Aims What is a Priority Setting Partnership
More informationThe James Lind Alliance Guidebook
The James Lind Alliance Guidebook Written by Katherine Cowan and Sandy Oliver www.jlaguidebook.org 0 Welcome to the James Lind Alliance Guidebook. The Guidebook provides step-by-step guidance to establishing
More informationEvaluation of the Type 1 Diabetes Priority Setting Partnership
Evaluation of the Type 1 Diabetes Priority Setting Partnership Introduction The James Lind Alliance (JLA) Type 1 Diabetes Priority Setting Partnership (PSP) was established in 2010. The PSP began its process
More informationAffiliates Newsletter April 2009
MESSAGE FROM THE CHAIR Dear Colleague, Welcome to our second Affiliates Newsletter of 2009. We are currently in the process of finalising our Business Plan for our third year to March 2010 and I am delighted
More informationWe are currently recruiting new members to advisory groups for the following research programmes:
Information for applicants to join NIHR as an advisory group member: HTA Programme Topic Identification, Development and Evaluation (TIDE) panel Chairs 1. Background information The goal of the National
More informationLichen Sclerosus Priority Setting Partnership. Steering Group Member Biographies
Lichen Sclerosus Priority Setting Partnership Steering Group Member Biographies Patient representative/s: Suzanne Larsen Suzanne is the Founder and Chairman of the Danish Lichen Sclerosus Association.
More informationBritish Association of Stroke Physicians Strategy 2017 to 2020
British Association of Stroke Physicians Strategy 2017 to 2020 1 P age Contents Introduction 3 1. Developing and influencing local and national policy for stroke 5 2. Providing expert advice on all aspects
More informationWhite Rose Research Online URL for this paper: Version: Accepted Version
This is a repository copy of Establishing and Prioritising Research Questions for the Prevention, Diagnosis and Treatment of Hair Loss (excluding Alopecia Areata): The Hair Loss Priority Setting Partnership..
More informationType 2 diabetes Priority Setting Partnership (PSP) FREQUENTLY ASKED QUESTIONS
Type 2 diabetes Priority Setting Partnership (PSP) FREQUENTLY ASKED QUESTIONS What is a Priority Setting Partnership (PSP)? Priority Setting Partnerships focus on a particular condition or healthcare issue.
More informationPatient and Carer Network. Work Plan
Patient and Carer Network Work Plan 2016 2020 Introduction from our chair When it was established over a decade ago, the RCP s Patient and Carer Network (PCN) led the way in mapping and articulating the
More informationThe Palliative and end of life care Priority Setting Partnership with the James Lind Alliance (PeolcPSP)
The Palliative and end of life care Priority Setting Partnership with the James Lind Alliance (PeolcPSP) An example for determining research priorities from the perspective of the end user of research
More informationPatient-Centred Research Priorities Relating to Healthcare of Frail Older Canadians
Patient-Centred Research Priorities Relating to Healthcare of Frail Older Canadians Canadian Frailty Network Annual National Conference April 24, 2017 Jennifer Bethell, Martine Puts, Katherine McGilton,
More informationTHE JAMES LIND ALLIANCE Tackling treatment uncertainties together
An Introduction to THE JAMES LIND ALLIANCE Tackling treatment uncertainties together Summary Despite the vast amount of research on the effects of treatments in health care, many uncertainties remain.
More informationVersion 1.0. Prostate Cancer Priority Setting Partnership
Version 1.0 Prostate Cancer Priority Setting Partnership Prostate Cancer Priority Setting Partnership The Prostate Cancer Research Foundation (PCRF) and the Prostate Cancer Support Federation (PCSF), in
More informationPrioritising uncertainties assembled in UK DUETs, for additional research. NHS Evidence provided by NICE
Prioritising uncertainties assembled in UK DUETs, for additional research NHS Evidence provided by NICE James Lind Alliance Tackling treatment uncertainties together Patients and Clinicians James Lind,
More informationHEALTH AND SPORT COMMITTEE AGENDA. 14th Meeting, 2018 (Session 5) Tuesday 1 May 2018
HS/S5/18/14/A HEALTH AND SPORT COMMITTEE AGENDA 14th Meeting, 2018 (Session 5) Tuesday 1 May 2018 The Committee will meet at 10.00 am in the James Clerk Maxwell Room (CR4). 1. Scottish Health Council Review:
More informationFamily Violence Integration Project. Eastern Community Legal Centre
Family Violence Integration Project Eastern Community Legal Centre Mid Term Report February 2012 Prepared by Clare Keating, Effective Change Pty Ltd Introduction Commencing in February 2011, the Family
More informationAdding Value to the NHS, Health and Care, through Research Management, Support & Leadership
Invitation to Comment This new draft strategy has been developed to ensure that the Forum continues to thrive, that we meet the needs of the community over the next five years, and that by acting together
More informationStrategic Plan
Strategic Plan 2015 18 President s message The Royal College of Psychiatrists is committed to improving the lives of people with mental illness. This strategic plan is based on the top three priorities
More informationWELSH GOVERNMENT RESPONSE TO RECOMMENDATIONS FROM THE HEALTH & SOCIAL CARE COMMITTEE: INQUIRY INTO NEW PSYCHOACTIVE SUBSTANCES
WELSH GOVERNMENT RESPONSE TO RECOMMENDATIONS FROM THE HEALTH & SOCIAL CARE COMMITTEE: INQUIRY INTO NEW PSYCHOACTIVE SUBSTANCES Recommendation 1 The Committee recommends that the Minister for Health and
More informationImproving Hospital Outcomes through Patient Engagement: the i-hope study
Improving Hospital Outcomes through Patient Engagement: the i-hope study The webinar will begin shortly please enter your audio PIN if you wish to introduce yourself or ask questions As a reminder please
More informationStrategic Plan: Implementation Work Plan
Healthy Eating Active Living New Hampshire Strategic Plan: Implementation Work Plan July 1, 2011 June 30, Adopted: July 28, 2011 Goal One: Increase the number and effectiveness of community coalitions
More informationJames Lind Alliance. Tackling treatment uncertainties together (Patients and Clinicians) The Why The What The How The Questions The Future
James Lind Alliance Tackling treatment uncertainties together (Patients and Clinicians) The Why The What The How The Questions The Future James Lind Alliance Tackling Treatment Uncertainties Together The
More informationSouth Norfolk CCG Dementia Strategy and Action Plan Dr Tony Palframan, SNCCG Governing Body Member
Agenda item: 9.4 Subject: Presented by: Submitted to: South Norfolk CCG Dementia Strategy and Action Plan Dr Tony Palframan, SNCCG Governing Body Member Governing Body Date: 28 th July Purpose of paper:
More informationThe Greater Manchester Stroke Operational Delivery Network
The Dr Jane Molloy Clinical Lead What is the GMSODN? Established in July 2015 Only Stroke ODN in the country Non-statutory body constituted from all public sector stroke provider organisations across Greater
More informationLondon Association of Directors of Public Health Priorities for Collaboration September 2017 September 2018
ADPH London London Association of Directors of Public Health Priorities for Collaboration September 2017 September 2018 Improving and protecting the health of Londoners 1 Table of Contents Welcome 3 About
More informationAppendix 2 Good Relations Action Plan, Outcomes, Timescales
Appendix 2 Appendix 2 Good Relations Action Plan, Outcomes, Timescales Theme 1 Increasing Visibility Develop a public statement on the Trust s commitment to challenging sectarianism and racism in all its
More informationPeer counselling A new element in the ET2020 toolbox
shutterstock Peer counselling A new element in the ET2020 toolbox Information Note. Main characteristics of the peer counselling tool Peer learning in the context of the education cooperation at EU level
More informationA proposal for collaboration between the Psychometrics Committee and the Association of Test Publishers of South Africa
A proposal for collaboration between the Psychometrics Committee and the Association of Test Publishers of South Africa 27 October 2015 Table of contents Introduction... 3 Overview of the Association of
More informationHip and Knee Replacement for Osteoarthritis Priority Setting Partnership
Do you have unanswered questions or uncertainties about hip and/or knee replacement for osteoarthritis? Do you think that answering those questions through research will help to improve the lives of people
More informationROLE SPECIFICATION FOR MACMILLAN GPs
ROLE SPECIFICATION FOR MACMILLAN GPs November 2010 History of Macmillan GPs Macmillan Cancer Support has funded GP positions from the early 1990 s, following the success of our investment in supporting
More informationCommittee of Senior Representatives Tenth Meeting Oslo, Norway 11 December 2006
Committee of Senior Representatives Tenth Meeting Oslo, Norway 11 December 2006 Reference CSR 10/7.1/1 Title Proposed Terms of Reference for the EG on HIV/AIDS Submitted by Secretariat Summary / Note As
More informationESPA Directorate KPI Report: Quarter 1,
ESPA Directorate KPI : 2015 2016 Quarter 1, Compiled by ESPA Operations Manager The Key Performance Indicators (KPIs) detailed in this report give direction to the ESPA Directorate and its activities.
More informationJames Lind Alliance Performance Tracker April 2008 March 2009 Final 20 th April 2009
1 Deliver Setting Partnerships (formerly known as Working Partnerships) o High o Need to accelerate and drive efficiency o Key tool from which learning can emanate o Note JLA will concentrate on projects
More informationA PATIENT AND PUBLIC INVOLVEMENT STRATEGY RESEARCH DESIGN SERVICE NORTH WEST. November 2011 Version 2.0
A PATIENT AND PUBLIC INVOLVEMENT STRATEGY RESEARCH DESIGN SERVICE NORTH WEST November 2011 Version 2.0 Page 1 of 8 Our aim The overall aim of the NIHR Research Design Service North West (NIHR RDS NW) in
More informationPort of Portland Hillsboro Airport Master Plan Update Planning Advisory Committee Charter
Port of Portland Hillsboro Airport Master Plan Update Planning Advisory Committee Charter Charter Purpose The purpose of this charter is to define the role of the Planning Advisory Committee () within
More informationEngaging with our stakeholders
Engaging with our stakeholders Report to: Board Date: 27 June 2014 Report by: Report No: Jenny Copland, Senior Communications Adviser Agenda Item: 6.3 PURPOSE OF REPORT To propose a format and processes
More informationPatient and Public Involvement in Research
Patient and Public Involvement in Research What is it and why is it important to us? Dr Margaret O Hara, Trustee, @Know_HG margaret@pregnancysicknesssupport.org.uk What Is PPI? 3 levels of activity ENGAGEMENT
More informationLower Mid North Coast. Family Law Pathways Network. Terms of Reference
Lower Mid North Coast Family Law Pathways Network Terms of Reference 1 Contents 1. Aims & Objectives of the Network p3 2. The Auspice Organization p6 3. The Structure of the Network p7 4. Operational Procedures
More informationSaturday 22 nd October Sally Crowe, Co Chair James Lind Alliance
Saturday 22 nd October Sally Crowe, Co Chair James Lind Alliance Tackling treatment uncertainties together The team! ` It s democratic who pays for research anyway? ` It s consumerist more likely to fund
More informationTeaching British Sign Language in schools
Teaching British Sign Language in schools Final Report, July 2016 Main objectives and context The British Sign Language (Scotland) Act passed in September 2015 with the aim of promoting British Sign Language
More informationNational Cancer Peer Review Programme
National Cancer Peer Review Programme Julia Hill Acting Deputy National Co-ordinator What is Cancer Peer Review? A quality assurance process for cancer services. An integral part of Improving Outcomes
More informationViolent Crime Prevention Board Strategy. 26 September Violent Crime Prevention using Vision to Champion Progress
Violent Crime Prevention Board Strategy 26 September 2018 Violent Crime Prevention using Vision to Champion Progress Page2 Violent Crime Prevention Board (VCPB) Strategy 2018 to 2023 1. Introduction This
More informationEngaging People Strategy
Engaging People Strategy 2014-2020 Author: Rosemary Hampson, Public Partnership Co-ordinator Executive Lead Officer: Richard Norris, Director, Scottish Health Council Last updated: September 2014 Status:
More informationYou said we did. Our Healthier South East London. Dedicated engagement events
Our Healthier South East London You said we did This report summarises the deliberative events carried out in June and other engagement activities we have undertaken so far in developing the South East
More informationDRAFT VERSION I SAFEGUARDING CHILDRENS BOARD MARCH 2017 SOUTHWARK PREVENT DRAFT LOCAL DELIVERY PLAN Page 1
SAFEGUARDING CHILDRENS BOARD MARCH 017 SOUTHWARK PREVENT DRAFT LOCAL DELIVERY PLAN 017-019 Page 1 STRATEGIC OBJECTIVES 1 SUPPORT FOR COMMUNITIES Engagement with communities and voluntary/faith institutions
More informationSarah Ambe Team Manager, Healthwatch Bristol SA Alison Bolam GP Clinical Commissioning Area Lead (Bristol), BNSSG AB
Patient and Public Involvement Forum Minutes of the meeting held on Tuesday 17 th July 2018 at 2pm in the WG Grace Meeting Room, Lower Ground Floor, South Plaza, Marlborough Street, Bristol, BS1 3NX Minutes
More informationBritish Fertility Society. Clinical guidelines
Guidance producer: British Fertility Society Guidance Product: Clinical guidelines Date: 13 January 2011 Final Accreditation Report Contents Introduction... 3 Accreditation recommendation... 3 Reapplication
More informationItem No: 6. Meeting Date: Tuesday 12 th December Glasgow City Integration Joint Board Performance Scrutiny Committee
Item No: 6 Meeting Date: Tuesday 12 th December 2017 Glasgow City Integration Joint Board Performance Scrutiny Committee Report By: Susanne Millar, Chief Officer, Strategy & Operations / Chief Social Work
More informationReport to the Merton Clinical Commissioning Group Governing Body
MCCG Board : 27.09.12 Pt1 : 7.5 : Att 11 Report to the Merton Clinical Commissioning Group Governing Body Date of Meeting: Thursday, 27 th Agenda No: 7.5 ATTACHMENT 11 Title of Document: Implementation
More informationCORPORATE PLANS FOR CHILD PROTECTION AND LOOKED ATER CHILDREN AND YOUNG PEOPLE
NHS Highland Board 28 March 2017 Item 4.11 CORPORATE PLANS FOR CHILD PROTECTION AND LOOKED ATER CHILDREN AND YOUNG PEOPLE Report by Dr Stephanie Govenden Lead Doctor Child Protection and Looked After Children
More information1. Introductions, welcome and apologies, declarations of conflicts of interest
Notes of the Fifty Eighth meeting of INVOLVE held at the National Council for Voluntary Organisations (NCVO), Regent's Wharf, 8 All Saints Street, London N1 9RL Thursday 19 May 2011 Present: Richard Baker
More informationNewcastle Safeguarding Children Board Business Group Terms of Reference
Newcastle Safeguarding Children Board Business Group Terms of Reference 1. Purpose Newcastle Safeguarding Children Board (NSCB) Business Group will act as the executive business group on behalf of Newcastle
More informationRoyal College of Radiologists (RCR) Referral guidelines. Final Accreditation Report. Guidance producer: Guidance product: Date: 29 June 2010
Guidance producer: Royal College of Radiologists (RCR) Guidance product: Referral guidelines Date: 29 June 2010 Final Accreditation Report Contents Introduction... 3 Accreditation recommendation... 3 Implementation...
More informationCrisis Connections Crisis Line Phone Worker Training (Online/Onsite) Winter 2019
Crisis Connections Crisis Line Phone Worker Training (Online/Onsite) Winter 2019 20-Jan 21-Jan 22-Jan 23-Jan 24-Jan 25-Jan 26-Jan between January 14th - January 21st Please Note: The application deadline
More informationJOB DESCRIPTION. ImROC Business Manager (Mental Health Network) and Senior. Policy Manager (NHS Clinical Commissioners)
JOB DESCRIPTION Job Title: Location: Salary: Reports To: Accountable To: Team Administrator London 21,630 (plus London weighting) ImROC Business Manager (Mental Health Network) ImROC Business Manager (Mental
More informationPublished December 2015
Published December 2015 Contents Executive summary 3 1. Introduction The changing story of cancer 6 2. Current state Poor performance 7 Fragmentation and duplication 7 Existing and developing programme
More informationConsultation on the role of the Scottish Health Council
Consultation on the role of the Scottish Health Council What you told us and what we will do next March 2018 Healthcare Improvement Scotland 2018 Published March 2018 This document is licensed under the
More informationSteering Group meeting Mild-Moderate hearing loss Priority Setting Partnership
Steering Group meeting Mild-Moderate hearing loss Priority Setting Partnership Date/Time Type Attendees: Friday 19 th September 1pm Teleconference David Crowe (Chair) Dr Helen Henshaw Dr Melanie Ferguson
More informationBrief history of the development of the Framework on Sharing influenza viruses and access to vaccines and other benefits
Brief history of the development of the Framework on Sharing influenza viruses and access to vaccines and other benefits The Intergovernmental (IGM) Process Since the late 1940's, WHO has coordinated a
More informationJOB DESCRIPTION JOB TITLE: STATUS: HOURS: SALARY: HOLIDAY: LOCATION: REPORTS TO: DIRECT REPORTS: KEY INTERNAL RELATIONSHIPS:
JOB DESCRIPTION JOB TITLE: Senior Policy and Public Affairs Officer STATUS: Permanent contract HOURS: 37.5 hours per week 9:00am 5:30pm (JDRF operates a flexible working hours policy) SALARY: 29,800 per
More informationLions Gate Secondary Wastewater Treatment Plant
Lions Gate Secondary Wastewater Treatment Plant Lions Gate Public Advisory Committee June 26, 2012 Orbit 6241100 Lions Gate Secondary Wastewater Treatment Plant Building a working relationship with the
More informationCase scenarios: Patient Group Directions
Putting NICE guidance into practice Case scenarios: Patient Group Directions Implementing the NICE guidance on Patient Group Directions (MPG2) Published: March 2014 [updated March 2017] These case scenarios
More informationMinistry of Health and Long-Term Care. Palliative Care. Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW
Chapter 1 Section 1.08 Ministry of Health and Long-Term Care Palliative Care Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW # of Status of Actions Recommended Actions
More information3. How to involve consumers in trials and studies
MRC CTU Consumer Group Guidelines for involving consumers in MRC CTU cancer trials and studies 1. Who are consumers? In this context, we are talking about people affected by cancer. These may be people
More informationStandard Reporting Template
Appendix Seven Annual Report Template Standard Reporting Template London Region [North Central & East/North West/South London] Area Team 2017/2018 Patient Participation Enhanced Service Reporting Template
More informationVolunteering in NHSScotland Developing and Sustaining Volunteering in NHSScotland
NG11-07 ing in NHSScotland Developing and Sustaining ing in NHSScotland Outcomes The National Group for ing in NHS Scotland agreed the outcomes below which formed the basis of the programme to develop
More informationPOLICY BRIEFING. Prime Minister s challenge on dementia 2020 implementation plan
POLICY BRIEFING Prime Minister s challenge on dementia 2020 implementation plan Date: 14th March 2016 Author: Christine Heron LGiU associate Summary The Prime Minister s challenge on dementia contains
More informationRoyal Borough of Greenwich Safeguarding Adults Board Joint Strategic Plan and Action Plan
1 Royal Borough of Greenwich Safeguarding Adults Board Joint Strategic Plan and Action Plan 2017-2020 2 Strategy Version Log: Version Date Summary of Changes Version 1 03/17 Agreed at Board Action Plan
More informationNational Indigenous Women s Health Workshop
National Indigenous Women s Health Workshop An open, interactive, engagement forum to move towards a National Partnership as a united voice in Indigenous Women's Health. Funded by the Australian Government
More informationSolihull Safeguarding Adults Board & Sub-committees
Solihull Safeguarding Adults Board & Sub-committees 2016 Safeguarding Adults Board Solihull Safeguarding Adults Board [SSAB or the Board] was established in 2008. It is a multi-agency partnership comprising
More informationCollation of responses to GW. 1. Please state the definitions that you use for different forms of palliative and end of life services
Collation of responses to GW 1. Please state the definitions that you use for different forms of palliative and end of life services Palliative care is the active holistic care of patients with advanced
More informationPatient and Public Engagement Strategy
Patient and Public Engagement Strategy December 2017 Contents The Mind & Body Programme... 3 Executive summary... 4 Purpose and values... 5 Approach... 6 Progress... 7 Engagement mechanisms... 7 Engagement
More informationHOW ARE WE DOING? HEALTHWATCH CROYDON SURVEY OF STATUTORY AND VOLUNTARY PARTNERS JULY 2017
HOW ARE WE DOING? HEALTHWATCH CROYDON SURVEY OF STATUTORY AND VOLUNTARY PARTNERS JULY Executive Summary The intention of the survey was to get feedback from statutory and voluntary sector partners of Healthwatch
More informationCore Standard 24. Cass Sandmann Emergency Planning Officer. Pat Fields Executive Director for Pandemic Flu Planning
Trust Board Meeting Agenda Item 7 Date: 30 September 2009 Title of Report Recommendations (please outline the purpose of the report and the key issues for consideration/decision) Progress with Pandemic
More informationGuidance on colleague and patient questionnaires
Guidance on colleague and patient questionnaires 2 Revalidation is the process by which doctors must demonstrate to the General Medical Council (GMC), normally every five years, that they are up to date
More informationFunding research for the future
Funding research for the future Dr Helen Compton (helen.compton@nihr.ac.uk) Stakeholder Engagement Manager NIHR, Central Commissioning Facility The future of health and social care depends on today's research
More informationHow a Signs of Safety approach is changing practice in Norfolk. Andrea Brown Principal Social Worker Community Care- Live Tuesday 10 th May 2016
How a Signs of Safety approach is changing practice in Norfolk Andrea Brown Principal Social Worker Community Care- Live Tuesday 10 th May 2016 The Norfolk Context 2014 OFSTED What did we need to do? Address
More informationRoyal College of Physicians (RCP) National Clinical Guidelines for Stroke. Final Accreditation Report. Guidance producer: Guidance product:
Guidance producer: Royal College of Physicians (RCP) Guidance product: National Clinical Guidelines for Stroke Date: 29 June 2010 Final Accreditation Report Contents Contents... 2 Introduction... 3 Implementation...
More informationPatient and public involvement. Guidance for researchers
Patient and public involvement Guidance for researchers Contents What is patient and public involvement and why is it important? 3 Benefits of patient and public involvement for researchers 4 Levels of
More informationAlcohol Research UK Research Strategy
Alcohol Research UK Research Strategy 2015-18 Supporting research to reduce alcohol-related harm www.alcoholresearchuk.org Alcohol Research UK Research Strategy 2015-18 Foreword Professor Alan-Maryon Davies
More informationUK Power Networks. Vulnerable & Fuel Poor Focus Group 25 November 2014
UK Power Networks Vulnerable & Fuel Poor Focus Group 25 November 2014 Safety and housekeeping Objectives To ensure a clear understanding of our approach to supporting both vulnerable and fuel poor customers
More information